Back to Search
WILLIAM SHAKESPEARE, MD
MD
Anesthesiology Physician
NPI: 1528153152IndividualAccepts Medicare
Specialties, Licenses & Credentials
Anesthesiology PhysicianPrimary
Anesthesiology
Code: 207L00000X
7502033-1205(UT)
CMS Specialties
PrimaryANESTHESIOLOGY
Education
UNIVERSITY OF UTAH SCHOOL OF MEDICINE
Class of 2005
Research & Publications (20)
SAR of carbon-linked, 2-substituted purines: synthesis and characterization of AP23451 as a novel bone-targeted inhibitor of Src tyrosine kinase with in vivo anti-resorptive activity.
PMID 18179464·Chem Biol Drug Des·2008
8-other
Nalidixic acid-resistant Salmonella enterica serotype Typhi presenting as a primary psoas abscess: case report and review of the literature.
PMID 15695728·J Clin Microbiol·2005
5-case
Novel bone-targeted Src tyrosine kinase inhibitor drug discovery.
PMID 14579523·Curr Opin Drug Discov Devel·2003
6-review
Structure-based design of novel bicyclic nonpeptide inhibitors for the src SH2 domain.
PMID 11052784·J Med Chem·2000
8-other
Structure-based design of an osteoclast-selective, nonpeptide src homology 2 inhibitor with in vivo antiresorptive activity.
PMID 10944210·Proc Natl Acad Sci U S A·2000
7-preclinical
9-(Arenethenyl)purines as dual Src/Abl kinase inhibitors targeting the inactive conformation: design, synthesis, and biological evaluation.
PMID 19572547·J Med Chem·2009
7-preclinical
The Journal Club: Teaching professionalism through discussions based on the history of anesthesiology.
PMID 19417606·Anesthesiology·2009
8-other
Novel N9-arenethenyl purines as potent dual Src/Abl tyrosine kinase inhibitors.
PMID 18691885·Bioorg Med Chem Lett·2008
4-observational
Crystal structure of the T315I mutant of AbI kinase.
PMID 17718712·Chem Biol Drug Des·2007
7-preclinical
Activity of dual SRC-ABL inhibitors highlights the role of BCR/ABL kinase dynamics in drug resistance.
PMID 16754879·Proc Natl Acad Sci U S A·2006
8-other
Antiangiogenic and antitumor effects of SRC inhibition in ovarian carcinoma.
PMID 16951177·Cancer Res·2006
8-other
Src activation of Stat3 is an independent requirement from NF-kappaB activation for constitutive IL-8 expression in human pancreatic adenocarcinoma cells.
PMID 16871430·Angiogenesis·2006
8-other
Future anti-catabolic therapeutic targets in bone disease.
PMID 16831942·Ann N Y Acad Sci·2006
6-review
Vascular endothelial growth factor receptor-1 mediates migration of human colorectal carcinoma cells by activation of Src family kinases.
PMID 16685275·Br J Cancer·2006
8-other
Structural basis of Src tyrosine kinase inhibition with a new class of potent and selective trisubstituted purine-based compounds.
PMID 16492148·Chem Biol Drug Des·2006
4-observational
AP23846, a novel and highly potent Src family kinase inhibitor, reduces vascular endothelial growth factor and interleukin-8 expression in human solid tumor cell lines and abrogates downstream angiogenic processes.
PMID 16373705·Mol Cancer Ther·2005
7-preclinical
In vitro and in vivo activity of ATP-based kinase inhibitors AP23464 and AP23848 against activation-loop mutants of Kit.
PMID 15746079·Blood·2005
7-preclinical
Protein phosphorylation and signal transduction modulation: chemistry perspectives for small-molecule drug discovery.
PMID 16787325·Med Chem·2005
6-review
Data courtesy of the U.S. National Library of Medicine (NLM). Ltrl is not affiliated with or endorsed by NLM.
Contact & Hours
- Address
- 5121 S COTTONWOOD STREET, INTERMOUNTAIN MEDICAL CENTER
MURRAY, UT 84157 - Phone
- (801) 507-5248
Quick Facts
- NPI
- 1528153152
- Entity Type
- Individual
- Gender
- Male
- Medicare
- Accepted
- Specialties
- 1
- Locations
- 1
- Years in Practice
- 21
- Publications
- 20
Are you this provider?
Claim Your Profile